Prevalence and phenotype associations of complement factor I mutations in geographic atrophy.

age-related macular degeneration complement factor I factor I geographic atrophy reticular pseudodrusen

Journal

Human mutation
ISSN: 1098-1004
Titre abrégé: Hum Mutat
Pays: United States
ID NLM: 9215429

Informations de publication

Date de publication:
09 2021
Historique:
revised: 09 05 2021
received: 08 02 2021
accepted: 13 06 2021
pubmed: 22 6 2021
medline: 1 4 2022
entrez: 21 6 2021
Statut: ppublish

Résumé

Rare variants in the complement factor I (CFI) gene, associated with low serum factor I (FI) levels, are strong risk factors for developing the advanced stages of age-related macular degeneration (AMD). No studies have been undertaken on the prevalence of disease-causing CFI mutations in patients with geographic atrophy (GA) secondary to AMD. A multicenter, cross-sectional, noninterventional study was undertaken to identify the prevalence of pathogenic rare CFI gene variants in an unselected cohort of patients with GA and low FI levels. A genotype-phenotype study was performed. Four hundred and sixty-eight patients with GA secondary to AMD were recruited to the study, and 19.4% (n = 91) demonstrated a low serum FI concentration (below 15.6 μg/ml). CFI gene sequencing on these patients resulted in the detection of rare CFI variants in 4.7% (n = 22) of recruited patients. The prevalence of CFI variants in patients with low serum FI levels and GA was 25%. Of the total patients recruited, 3.2% (n = 15) expressed a CFI variant classified as pathogenic or likely pathogenic. The presence of reticular pseudodrusen was detected in all patients with pathogenic CFI gene variants. Patients with pathogenic CFI gene variants and low serum FI levels might be suitable for FI supplementation in therapeutic trials.

Identifiants

pubmed: 34153144
doi: 10.1002/humu.24242
pmc: PMC9290714
doi:

Substances chimiques

Complement Factor I EC 3.4.21.45

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1139-1152

Informations de copyright

© 2021 The Authors. Human Mutation published by Wiley Periodicals LLC.

Références

Invest Ophthalmol Vis Sci. 2013 Nov 08;54(12):7362-9
pubmed: 24114542
Eur J Hum Genet. 2009 Jan;17(1):100-4
pubmed: 18685559
Retina. 2016 Dec;36(12):2348-2356
pubmed: 27388725
Invest Ophthalmol Vis Sci. 2020 Jun 3;61(6):18
pubmed: 32516404
Hum Mutat. 2021 Sep;42(9):1139-1152
pubmed: 34153144
Eur J Immunol. 2010 Jan;40(1):172-85
pubmed: 19877009
JAMA Ophthalmol. 2017 Nov 1;135(11):1242-1249
pubmed: 29049463
Clin Exp Immunol. 2015 Aug;181(2):314-22
pubmed: 25124117
Science. 2005 Apr 15;308(5720):419-21
pubmed: 15761120
PLoS One. 2008 Jul 02;3(7):e2593
pubmed: 18596911
Mol Immunol. 2017 Apr;84:65-76
pubmed: 27939104
Proc Natl Acad Sci U S A. 2011 Aug 2;108(31):12839-44
pubmed: 21768352
Clin J Am Soc Nephrol. 2013 Apr;8(4):554-62
pubmed: 23307876
Ophthalmology. 2013 Apr;120(4):872-872.e4
pubmed: 23552084
Nat Genet. 2016 Feb;48(2):134-43
pubmed: 26691988
Immunobiology. 2019 Jul;224(4):511-517
pubmed: 31109748
Kidney Int. 2010 Feb;77(4):339-49
pubmed: 20016463
Ann Allergy Asthma Immunol. 2020 Nov;125(5):613-614
pubmed: 32687990
Nat Genet. 2011 Oct 23;43(12):1232-6
pubmed: 22019782
Ophthalmology. 2010 Sep;117(9):1775-81
pubmed: 20472293
Mol Vis. 2014 Sep 13;20:1253-7
pubmed: 25352734
Hum Mol Genet. 2020 Aug 11;29(14):2313-2324
pubmed: 32510551
Mol Immunol. 2007 Mar;44(8):1835-44
pubmed: 17084897
J Clin Invest. 1996 Feb 15;97(4):925-33
pubmed: 8613545
Hum Mol Genet. 2015 Jul 1;24(13):3861-70
pubmed: 25788521
JAMA. 2004 Feb 11;291(6):704-10
pubmed: 14871913
Hum Mol Genet. 2005 Nov 1;14(21):3227-36
pubmed: 16174643
Nephrol Dial Transplant. 2013 Sep;28(9):2237-45
pubmed: 23787556
Mol Immunol. 2008 May;45(10):2764-71
pubmed: 18374984
Mol Immunol. 2008 Jan;45(1):95-105
pubmed: 17597211
Invest Ophthalmol Vis Sci. 2009 Dec;50(12):5818-27
pubmed: 19661236
Lancet. 2012 May 5;379(9827):1728-38
pubmed: 22559899
Hum Mol Genet. 2014 Oct 1;23(19):5283-93
pubmed: 24847005
Ophthalmology. 2014 Apr;121(4):917-25
pubmed: 24332537
Nat Genet. 2013 Jul;45(7):813-7
pubmed: 23685748
Ophthalmology. 2015 Aug;122(8):1555-62
pubmed: 26077580
Retina. 2010 Oct;30(9):1441-54
pubmed: 20924263
Eur J Immunol. 2009 Jan;39(1):310-23
pubmed: 19065647
JAMA Ophthalmol. 2015 May;133(5):581-8
pubmed: 25764262
Nat Commun. 2020 Feb 7;11(1):778
pubmed: 32034129
Ophthalmic Genet. 2017 May-Jun;38(3):245-251
pubmed: 27484132
Science. 2015 Jan 9;347(6218):1254806
pubmed: 25525159
Nat Genet. 2007 Oct;39(10):1200-1
pubmed: 17767156
Adv Exp Med Biol. 2012;724:15-36
pubmed: 22411231
Lancet Glob Health. 2014 Feb;2(2):e106-16
pubmed: 25104651
JAMA Ophthalmol. 2018 Jun 1;136(6):682-688
pubmed: 29801032
Br J Ophthalmol. 2012 May;96(5):752-6
pubmed: 22329913
Brief Funct Genomics. 2014 Sep;13(5):353-61
pubmed: 25005607
Immunobiology. 2016 Oct;221(10):1124-30
pubmed: 27268256
Science. 2005 Apr 15;308(5720):421-4
pubmed: 15761121
Orphanet J Rare Dis. 2012 Jun 18;7:42
pubmed: 22710145
Hum Mutat. 2010 Jun;31(6):E1445-60
pubmed: 20513133
Invest Ophthalmol Vis Sci. 2011 Aug 24;52(9):5009-15
pubmed: 21498612
JAMA Ophthalmol. 2016 Mar;134(3):287-93
pubmed: 26767664
Ann Hum Genet. 2010 Jan;74(1):17-26
pubmed: 20059470
Oncotarget. 2018 Jan 3;9(9):8502-8511
pubmed: 29492211
Retina. 2013 Feb;33(2):265-76
pubmed: 23266879
Proc Natl Acad Sci U S A. 2010 Apr 20;107(16):7401-6
pubmed: 20385819
Nat Rev Genet. 2009 Apr;10(4):241-51
pubmed: 19293820
Nat Genet. 2013 Nov;45(11):1366-70
pubmed: 24036952
J Am Soc Nephrol. 2005 Jul;16(7):2150-5
pubmed: 15917334
Surv Ophthalmol. 2016 Sep-Oct;61(5):521-37
pubmed: 26994868
Invest Ophthalmol Vis Sci. 2012 Mar 09;53(3):1258-63
pubmed: 22222508

Auteurs

Adnan H Khan (AH)

Division of Clinical Neurosciences, Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.
Southampton Eye Unit, University Hospital Southampton NHS Foundation Trust, Southampton, UK.

Janice Sutton (J)

Division of Clinical Neurosciences, Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.

Angela J Cree (AJ)

Division of Clinical Neurosciences, Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.

Samir Khandhadia (S)

Southampton Eye Unit, University Hospital Southampton NHS Foundation Trust, Southampton, UK.

Gabriella De Salvo (G)

Southampton Eye Unit, University Hospital Southampton NHS Foundation Trust, Southampton, UK.

John Tobin (J)

Gyroscope Therapeutics Limited, Stevenage, UK.

Priya Prakash (P)

The Eye Unit, The Princess Alexandra Hospital NHS Trust, Harlow, UK.

Rashi Arora (R)

Department of Ophthalmology, Salisbury District Hospital, Salisbury NHS Foundation Trust, Salisbury, UK.

Winfried Amoaku (W)

Eye and ENT Centre, Queen's Medical Centre, Nottingham University Hospitals NHS Trust, Nottingham, UK.

Peter Charbel Issa (P)

Oxford Eye Hospital and Oxford NIHR Biomedical Research Centre, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Nuffield Laboratory of Ophthalmology, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.

Robert E MacLaren (RE)

Oxford Eye Hospital and Oxford NIHR Biomedical Research Centre, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Nuffield Laboratory of Ophthalmology, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.

Paul N Bishop (PN)

Division of Evolution and Genomic Sciences, Faculty of Medicine and Health, School of Biological Sciences, University of Manchester, Manchester, UK.
Manchester Royal Eye Hospital, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.

Tunde Peto (T)

Centre for Public Health, School of Medicine, Institute of Clinical Sciences, Queen's University Belfast, Belfast, UK.

Quresh Mohamed (Q)

Department of Ophthalmology, Gloucestershire Royal Hospital, Gloucestershire Hospitals NHS Foundation Trust, Gloucester, UK.

David H Steel (DH)

Sunderland Eye Infirmary, South Tyneside and Sunderland NHS Foundation Trust, Sunderland, UK.
Biosciences Institute, Newcastle University, Newcastle upon Tyne, UK.

Sobha Sivaprasad (S)

Institute of Ophthalmology, University College London, London, UK.

Clare Bailey (C)

Clinical Research Unit, Bristol Eye Hospital, University Hospitals Bristol NHS Foundation Trust, Bristol, UK.

Geeta Menon (G)

Department of Ophthalmology, Frimley Park Hospital, Frimley Health NHS Foundation Trust, Camberley, UK.

David Kavanagh (D)

National Renal Complement Therapeutics Centre, Royal Victoria Infirmary, Newcastle upon Tyne, UK.
Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.

Andrew J Lotery (AJ)

Division of Clinical Neurosciences, Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.
Southampton Eye Unit, University Hospital Southampton NHS Foundation Trust, Southampton, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH